MacroGenics Inc. Files Amended Pro Forma Financials; CDMO Disposition

What Happened
MacroGenics, Inc. (MGNX) filed an amended Form 8-K on September 3, 2026, submitting amended and restated unaudited pro forma consolidated financial statements that reflect the disposition of its CDMO Operations as a discontinued operation. The filing updates the company’s historical presentation and revises estimates and assumptions previously reported in an earlier 8-K.

Key Details

• The filing includes an amended and restated unaudited pro forma consolidated balance sheet as of March 31, 2026.
• It also includes amended and restated unaudited pro forma consolidated statements of operations for: the three months ended March 31, 2026, and the years ended December 31, 2025, 2024 and 2023.
• The pro forma statements treat the CDMO Operations as discontinued operations and reflect changes in estimates/assumptions from the Original 8-K.
• The amendment was filed as Exhibit 99.1 to the Form 8-K and the report was signed by Jeffrey Peters, SVP, General Counsel and Corporate Secretary.

Why It Matters
This filing gives investors updated, comparable historical financials that exclude the CDMO business and show how prior results are reclassified under discontinued operations. That affects how revenue, earnings and other operating metrics are compared across periods and may change analysts’ adjusted earnings or trend analysis. Investors should review the pro forma statements (Exhibit 99.1) to understand the magnitude of the adjustments and how the company’s continuing operations now present going forward.